Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Letter: can addition of an immunomodulator really reverse antibody formation and loss of response in patients treated with adalimumab?

Research output: Contribution to journalLetterResearchpeer-review

DOI

  1. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. All-cause and cause-specific mortality in microscopic colitis: a Danish nationwide matched cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Comparison of infliximab with adalimumab in 827 biologic-naïve patients with Crohn's disease: a population-based Danish cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Pattern recognition receptor polymorphisms in early periodontitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations
Original languageEnglish
JournalAlimentary Pharmacology and Therapeutics
Volume45
Issue number5
Pages (from-to)759-760
Number of pages2
ISSN0269-2813
DOIs
Publication statusPublished - Mar 2017

    Research areas

  • Adalimumab, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antibody Formation, Humans, Immunologic Factors, Infliximab, Treatment Outcome, Letter

ID: 52406846